Breaking News

TransAsia Air Flight Crashed in Taiwan, Official Confirms
Tweet TWEET

Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule

Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of
Schedule

THE WOODLANDS, Texas, May 2, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc.^® (Nasdaq:RPRX) today announced it has fully enrolled the 180 subject
second pivotal study (ZA-302) for Androxal® one month ahead of schedule.
Androxal is being studied as an oral therapy for the treatment of secondary
hypogonadism.

The Company expects to have topline results from the study during the fourth
quarter of this year.

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including the ability to raise additional needed capital on a
timely basis in order for it to continue to fund development of its Androxal^®
and Proellex^® programs, have success in the clinical development of its
technologies, the reliability of interim results to predict final study
outcomes, and such other risks which are identified in the Company's most
recent Annual Report on Form 10-K and in any subsequent quarterly reports on
Form 10-Q. These documents are available on request from Repros Therapeutics
or at www.sec.gov. Repros disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

For more information, please visit the Company's website at
http://www.reprosrx.com.

CONTACT: Repros Therapeutics Inc.
         Joseph Podolski (281) 719-3447
         President and Chief Executive Officer
        
         Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931

company logo